Literature DB >> 6336974

Malignant lymphoma of true histiocytic (monocyte/macrophage) origin.

P Isaacson, D H Wright, D B Jones.   

Abstract

Since the advent of the newer classifications of non-Hodgkin's lymphoma and the realization that the majority of tumors classified as histiocytic under the Rappaport classification were in fact of lymphocytic origin, there have been remarkably few reports of true histiocytic (monocyte/macrophage) tumors and it has been suggested by some that such tumors should not be considered as a variety of malignant lymphoma. This article describes five patients with malignant lymphoma of neither B- or T-lymphocyte origin in whom the malignant cells could be characterised immunologically, cytochemically, and immunohistochemically as of true histiocytic derivation. The cases showed considerable morphologic diversity but there were shared characteristics at both light microscopic and ultrastructural levels. Positive immunohistochemical staining for alpha 1-antitrypsin was the single most useful criterion in classifying these tumors. Without the use of special techniques there were no clinical or pathologic features that reliably distinguished these cases from non-Hodgkin's lymphomas of lymphocytic derivation. Tumors of histiocytic origin are, therefore, inevitably being included among the non-Hodgkin's lymphomas and are most appropriately classified as such. Identification of histiocytic lymphomas should be encouraged so prognosis and optimum treatment can be established.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6336974     DOI: 10.1002/1097-0142(19830101)51:1<80::aid-cncr2820510118>3.0.co;2-0

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  16 in total

1.  Unfixed tissue for electron immunocytochemistry: a simple preparation method for colloidal gold localization of sensitive epitopes using ethanediol dehydration.

Authors:  J W Stirling
Journal:  Histochem J       Date:  1992-04

2.  Heterogeneous malignant non Hodgkin's lymphomas as a causative disorder in lethal midline granuloma.

Authors:  R H Laeng; H A Gerber; T Schaffner; K H Bürki
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1989

3.  Immunohistological analysis of Rosai-Dorfman histiocytosis. A disease of S-100 + CD1-histiocytes.

Authors:  F Bonetti; M Chilosi; F Menestrina; A Scarpa; P G Pelicci; E Amorosi; L Fiore-Donati; D M Knowles
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1987

4.  Diagnosing tumours on routine surgical sections by immunohistochemistry: use of cytokeratin, common leucocyte, and other markers.

Authors:  R N Poston; Y S Sidhu
Journal:  J Clin Pathol       Date:  1986-05       Impact factor: 3.411

Review 5.  Non-Hodgkin's lymphoma.

Authors:  S C Gulati; C Gulati; R Vega; L Gandola; J Yopp; R Dinsmore; R O'Reilly; B Clarkson
Journal:  Indian J Pediatr       Date:  1983 Nov-Dec       Impact factor: 1.967

6.  A journey into insidious world of MALT lymphoma of the ileum: from the beginning to the end.

Authors:  Anil Kumar Dhull; Vivek Kaushal; Sunita Singh; Manoj Pal; Amit Lathwal
Journal:  J Gastrointest Oncol       Date:  2014-12

7.  Immunofluorescence study of secretory epithelial markers in pleomorphic adenomas.

Authors:  F R Korsrud; P Brandtzaeg
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1984

8.  Targeting of transgene expression to monocyte/macrophages by the gp91-phox promoter and consequent histiocytic malignancies.

Authors:  D G Skalnik; D M Dorfman; A S Perkins; N A Jenkins; N G Copeland; S H Orkin
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

9.  Immunohistochemical findings in rheumatoid nodules.

Authors:  M J Aherne; P A Bacon; D R Blake; P J Gallagher; D B Jones; C J Morris; A R Potter
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1985

10.  Alpha-1 anti-trypsin and CD30 expression occur in parallel in activated T cells.

Authors:  M S Bashir; D B Jones; D H Wright
Journal:  Clin Exp Immunol       Date:  1992-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.